FNY Investment Advisers LLC Makes New Investment in Novo Nordisk A/S (NYSE:NVO)

FNY Investment Advisers LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 8,972 shares of the company's stock, valued at approximately $623,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Center for Financial Planning Inc. grew its position in shares of Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after buying an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL boosted its stake in Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after acquiring an additional 300 shares in the last quarter. Park Square Financial Group LLC purchased a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $29,000. Transce3nd LLC purchased a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $33,000. Finally, CX Institutional acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth about $36,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock traded down $2.81 during trading hours on Monday, hitting $77.02. 8,140,859 shares of the company were exchanged, compared to its average volume of 7,046,879. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The business has a 50-day moving average of $67.30 and a 200-day moving average of $79.45. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15. The stock has a market capitalization of $345.62 billion, a price-to-earnings ratio of 23.41, a P/E/G ratio of 0.90 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The company had revenue of $11.87 billion during the quarter. As a group, analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analysts Set New Price Targets

NVO has been the subject of a number of research analyst reports. BNP Paribas assumed coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating for the company. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Wall Street Zen upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday. Guggenheim downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Finally, Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.